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Abstract: The purpose of this review was to test contraceptive efﬁ  cacy, cycle control, 
tolerability, and acceptability as found in the non-comparative studies with NuvaRing® by 
those found in the randomized trials comparing NuvaRing and combined oral contraceptives 
(COCs). All large non-comparative studies and all relevant randomized controlled trials (RCTs) 
between NuvaRing and a COC up to and including December 2006 were analyzed. Two large 
multi-center registration studies, 1 large daily clinical practice study, and 6 RCTs compar-
ing NuvaRing and a COC were identiﬁ  ed. The ﬁ  ndings in the non-comparative studies were 
conﬁ  rmed in the RCTs. Contraceptive efﬁ  cacy was high showing no signiﬁ  cant differences in 
comparison with the COC; cycle control was good and consistently better than that of the COC; 
compliance was high and comparable with that of the pill; the incidence of adverse events such 
as breast tenderness, headache, and nausea was low, but not lower than with the COC despite 
a halving of the systemic exposure to ethinyl estradiol (EE) with NuvaRing compared with a 
30-µg EE-containing COC; the incidence of local and ring-related events was low but higher 
than with the COC, leading to higher discontinuation rates among NuvaRing users; acceptability 
was high and comparable between both contraceptives, resulting in a global improvement of 
sexual function with both methods. After study completion, women using NuvaRing were more 
likely to continue with their method than women using a COC. The good results with respect 
to contraceptive efﬁ  cacy, cycle control, tolerability, and acceptability as achieved with NuvaR-
ing in the large non-comparative registration studies were conﬁ  rmed in the RCTs comparing 
NuvaRing with different COCs.
Keywords: acceptability, contraceptive efﬁ  cacy, cycle control, NuvaRing, tolerability, vaginal 
ring
Introduction
The combined contraceptive vaginal ring (CCVR, NuvaRing®, Organon Int., Oss, The 
Netherlands) is a new once-a-month method of hormonal contraception. It consists of 
a ﬂ  exible, soft, transparent, ring measuring 54 mm in diameter and 4 mm thickness 
which can easily be inserted by the woman herself into the vagina (see Fig. 1). After 
3 weeks of use the woman removes the ring, thereby introducing a ring-free week 
during which a withdrawal bleeding normally occurs.
The ring is made of the copolymer evatane, in which the hormones ethinyl estra-
diol (EE, 2.7 mg) and etonogestrel (ENG, 11.7 mg) are equally dispersed. ENG is 
3-ketodesogestrel, which is the active metabolite of the progestin desogestrel. Due 
to the composition of the ring, it steadily releases 15 µg EE and 120 µg ENG daily 
which are then continuously absorbed through the vaginal epithelium. Vaginal admin-
istration of contraceptive hormones with NuvaRing has the advantage of avoiding 
gastrointestinal absorption and hepatic ﬁ  rst-pass metabolism, but does not produce 
elevated uterine concentrations of EE and ENG compared with a COC (Roumen and 
Dieben 2006). Compared with a COC containing 150 µg desogestrel and 30 µg EE, Therapeutics and Clinical Risk Management 2008:4(2) 442
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systemic exposure to ENG is similar for NuvaRing, whereas 
systemic exposure to EE with NuvaRing is approximately 
50% of that for the COC (Timmer and Mulders 2000; van 
den Heuvel et al 2005). Ovulation suppression, as assessed 
by follicular diameter and serum hormone levels, is compa-
rable (Mulders and Dieben 2001) or slightly lower (Duijkers 
et al 2004) between NuvaRing and COC use. Ovulations, 
however, do not occur (Duijkers et al 2004).
Contraceptive efﬁ  cacy, cycle control, tolerability, and 
acceptability of NuvaRing have been established in several 
large non-comparative multi-center registration studies 
(Roumen et al 2001; Dieben et al 2002), and in daily clini-
cal practice (Roumen et al 2006). It is interesting to ﬁ  nd out 
whether the results of these studies could be conﬁ  rmed in 
randomized controlled trials (RCTs) comparing NuvaRing 
with COCs, as the working mechanism (ovulation inhibition) 
and the contraindications for both methods are very similar. 
Up to and including December 2006, the results of 6 such 
trials have been published in 10 peer-reviewed articles. The 
results of the non-comparative studies will be compared with 
those of these RCTs, and reviewed here.
Contraceptive efﬁ  cacy
Contraceptive efﬁ  cacy with NuvaRing was examined in two 
1-year, open-label, non-comparative studies conducted in 52 
Western European centers and in 48 centers in the US and 
Canada, involving nearly 1200 women each (Roumen et al 
2001; Dieben et al 2002). Throughout the study period, less 
unwanted pregnancies occurred in Western Europe (n = 6) 
than in North America (n = 15). The Pearl indices for the 
intent-to-treat (ITT) populations were 0.65 in the European 
study, and 1.75 in the American study (Table 1). The method-
related Pearl indices were lower: 0.40 (95% CI 0.08–1.16), 
and 1.27 (95% CI 0.51–2.62), respectively. Pooling the 
pregnancies of both studies together resulted in a Pearl index 
of 1.18 (95% CI 0.73–1.80). The overall cumulative preg-
nancy rate of in-treatment pregnancy, derived from life table 
analysis, was 1.18% (95% CI 0.68–1.69), and comparable 
Figure 1 The combined contraceptive vaginal ring (NuvaRing®).Therapeutics and Clinical Risk Management 2008:4(2) 443
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with the Pearl index. The pooled method-related Pearl index 
was 0.77 (95% CI 0.37–1.40).
Occurrence of pregnancy was also determined in a 
Phase III, open-label, group-comparative, multi-center trial 
conducted in 9 European and 2 South American countries 
(Oddsson et al 2005a). In this study, 1030 women were ran-
domized to 13 cycles of treatment with NuvaRing (n = 512) or 
a 150 levonorgestrel (LNG)/30EE COC (n = 518) and com-
prised the ITT population. The per protocol (PP) population 
comprised 899 subjects (NuvaRing = 440; COC = 459). A 
total of 10 pregnancies occurred during treatment in the ITT 
population (NuvaRing = 5; COC = 5). Of these, 3 subjects 
in the NuvaRing group and 2 subjects in the COC group had 
no protocol violations or only minor protocol violations that 
occurred after the estimated date of conception, reducing the 
number of PP in-treatment pregnancies to 5 (NuvaRing = 3; 
COC = 2), with no signiﬁ  cant difference between PP treat-
ment groups. The Pearl indices for the ITT populations were 
1.23 and 1.19 per 100 women-years for the ring and COC 
groups, respectively (Table 1). No signiﬁ  cant difference 
was found between the two treatment groups. The estimated 
cumulative probabilities of in-treatment ITT pregnancy after 
cycle 13 were 1.20% (95% CI 0.14–2.26%) for the ring group 
and 1.07% (95% CI 0.13–2.00%) for the COC group. For 
the PP population, the estimated probabilities were 0.71% 
(95% CI 0.00–1.52%) and 0.43% (95% CI 0.00–1.01%) for 
the ring and COC groups, respectively. The results show 
therefore that contraceptive efﬁ  cacy was comparable for 
NuvaRing and this COC.
These results were confirmed in another open-
label, group-comparative, multi-center trial conducted in 
10 countries in Europe (Ahrendt et al 2006). In this study, 
983 women were randomly treated with NuvaRing (n = 499) 
or a COC containing 3 mg drospirenone and 30 µg EE 
(DRSP/30EE) (n = 484) for 13 cycles (ITT population). 
There were 5 pregnancies during the study, 1 in the NuvaR-
ing group and 4 in the COC group. Two pregnancies in 
the COC group were associated with protocol violations. 
Pearl indices for the ITT population were 0.25 and 0.99 
per 100 women-years for the NuvaRing and COC groups, 
respectively (Table 1). These results were not signiﬁ  cantly 
different (p = 0.37).
Cycle control
Bleeding patterns were evaluated in the two 1-year, open-
label, non-comparative studies conducted in 52 Western 
European centers and in 48 centers in the US and Canada 
(Roumen et al 2001; Dieben et al 2002). Combining the data 
of the PP populations of both studies resulted in a withdrawal 
bleeding in 98.5% of women (95% CI 97.7%–99.0%); early 
withdrawal bleeding (starting before the ring-free week) in 
6.1% of women (95% CI 5.1%–8.4%); and late withdrawal 
bleeding (persisting after the ring-free week) in 23.9% of 
women (95% CI 20.5%–26.5%). In most women, early or 
late withdrawal bleeding was restricted to spotting only. The 
incidence of irregular bleeding was very low, with an average 
of 5.5% per cycle over cycles 1–13, and slightly declining 
during the study. Irregular bleeding was less frequent in the 
European study (4.4% of women per cycle) than in the North 
American study (7.0% of women per cycle). In the majority 
of cycles, the irregular bleeding was restricted to spotting 
only. Cycles with an “intended bleeding pattern”, deﬁ  ned as 
a cycle with a withdrawal bleeding in the ring-free week, no 
early withdrawal bleeding or continued withdrawal bleeding, 
and no irregular bleeding, can be calculated to be 63.0% in 
the combined data.
Bleeding patterns were also examined in an observational 
study among 854 women in The Netherlands who started 
with NuvaRing (Roumen et al 2006). In the subgroup of 
participants who had previously used a COC (86.8%), the 
percentage of women who reported irregular blood loss dur-
ing the ﬁ  rst three NuvaRing cycles decreased from 32% to 
16% (p   0.0001) (spotting from 20% to 9%, and bleeding 
from 12% to 7%). In total, after 3 cycles, 42% of the ring 
users reported a decrease in blood loss during the ring-free 
week compared with the pill-free week following the end of 
a cycle of COC use, whereas 12% of the ring users reported 
an increase. In 39% of the cases, after 3 cycles of ring use 
the blood loss was reported to be of shorter duration.
Table 1 Contraceptive efﬁ  cacy with NuvaRing in 2 non-comparative 
studies, and in 2 randomized controlled trials comparing NuvaRing 
with 2 different COCs: 150LNG/30EE and DRSP/30EE (ITT popu-
lation)
Study Method (number 
of participants)
Pearl 
index
95% CI
Roumen et al 2001 NuvaRing (n = 1145) 0.65 0.24–1.41
Dieben et al 2002 NuvaRing (n = 1177) 1.75 0.98–2.89
Oddsson et al 2005a NuvaRing (n = 512)
150LNG/30EE COC
(n = 518)
1.23
1.19
0.40–2.86
0.39–2.79
Ahrendt et al 2006  NuvaRing (n = 499) 0.25 0.01–1.36
DRSP/30EE COC
(n = 484)
0.99 0.27–2.53
Abbreviations: CI, conﬁ  dence interval; COCs, combined oral contraceptives; 
DRSP, drospirenone; EE, ethinyl estradiol; ITT, intent-to-treat; LNG, levonorgestrel.Therapeutics and Clinical Risk Management 2008:4(2) 444
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Data on cycle control with NuvaRing versus the 
150LNG/30EE COC were obtained in the randomized, 
comparative, multicenter, Phase III study conducted in 11 
countries (Oddsson et al 2005a, b). In the ITT analysis, 
the incidence of breakthrough bleeding and spotting over 
cycles 2–13, the primary efﬁ  cacy parameter, was lower 
with NuvaRing (range 2.0%–6.4%) than the COC (range 
3.5%–12.6%), and for cycles 2 and 9 the lower incidence 
with NuvaRing was conﬁ  rmed as statistically signiﬁ  cant 
(p   0.003). As shown in Table 2, the incidence of 
intended bleeding pattern was signiﬁ  cantly higher over 
all cycles with NuvaRing (58.8%–72.8%) than with the 
COC (43.4%–57.9%) (p   0.005). This was mainly due 
to a lower incidence of continued withdrawal bleeding for 
the NuvaRing group (21.7%–27.3%) than the COC group 
(33.8%–39.0%) in cycles 1–13 and this was statistically 
signiﬁ  cant for all cycles (p   0.02). Continued withdrawal 
bleeding with spotting days occurred less frequently in 
the NuvaRing group (16.2%–23.2%) in cycles 1–13 and 
was statistically signiﬁ  cant for cycles 1, 3–7, 9, 10, and 12 
(p   0.05) compared with the COC group (25.6%–30.7%). 
There was no signiﬁ  cant difference in the incidence of 
early withdrawal bleeding or spotting between both treat-
ment groups.
Cycle control was also studied in the women participat-
ing in the European open-label, group-comparative, multi-
center trial of Ahrendt et al (2006). A signiﬁ  cantly higher 
incidence of intended bleeding in the NuvaRing group 
(55.2%–68.5%) compared with the DRSP/30EE COC group 
(35.6%–56.6%) was found for each of the ITT cycles 1–12 
(p   0.01). Breakthrough bleeding or spotting during cycles 
2–13 ranged from 3.6% to 6.2% in the NuvaRing group and 
from 4.7% to 10.4% in the COC group. The incidence of 
breakthrough bleeding/spotting was lower with NuvaRing 
than with the COC for all cycles except cycles 11 and 12, 
but this did not achieve statistical signiﬁ  cance. However, 
signiﬁ  cantly fewer breakthrough spotting episodes were 
observed in the NuvaRing group during cycles 1, 3, 4, 6, and 
10 (p   0.05), whereas signiﬁ  cantly more early withdrawal 
bleedings were observed in the NuvaRing group compared 
with the COC group during cycles 1, 5, 8, and 12 (p   0.05). 
Between-group differences for continued withdrawal bleed-
ing were statistically signiﬁ  cant in each of cycles 1−12 in 
favor of NuvaRing (p   0.0001). In both groups, early and 
continued withdrawal bleeding consisted mainly of spotting 
days during the ring/pill period. The incidence of cycles 
(1−13) without withdrawal bleeding ranged from 0.2% to 
3.2% for NuvaRing users and from 0.5% to 1.7% for COC 
users, with no statistically signiﬁ  cant differences between 
the groups in any cycle.
Bleeding patterns were also studied using the Quick Start 
approach, which means that the contraceptive method is 
initiated immediately, at the time of the clinic visit, regard-
less of menstrual cycle day (Westhoff et al 2005). In an 
open-label, one-center, controlled trial, 201 women were 
randomly assigned to NuvaRing (ITT = 78) or a triphasic 
COC containing norgestimate (0.18 mg during the ﬁ  rst week; 
0.215 mg during the second week; 0.25 mg during the third 
week) and 25 µg EE (NOR/25EE) (ITT = 78). Using the 
standardized deﬁ  nitions of the clinically important WHO 
menstrual indices, which exclude any menstrual events in 
progress at the beginning and end of the reference period, 
the NuvaRing users experienced significantly fewer 
bleeding-spotting days (14.5 versus 19.2 days, respectively, 
p   0.001) during the 84-day reference period (three 28-day 
cycles). Ethnicity, weight, body mass index, and smoking 
were not associated with the number of bleeding-spotting 
days. In the COC group, however, there was a weak asso-
ciation between nulliparity and bleeding-spotting days, 
particularly for older nulliparous participants. No signiﬁ  cant 
differences in bleeding patterns were found based on analysis 
of cycle week at study enrolment. The difference in bleed-
ing-spotting days was largely attributable to a difference in 
bleeding, with NuvaRing users experiencing fewer bleeding-
only days (9.1 versus 11.9 days, respectively). The number 
of bleeding-spotting episodes was also signiﬁ  cantly lower 
(2.4 versus 3.0, respectively) in NuvaRing users, and their 
bleeding-spotting-free intervals were signiﬁ  cantly longer 
Table 2 The incidence of intended bleeding pattern – deﬁ  ned as 
cycles with a withdrawal bleeding, no early or continued withdrawal 
bleeding, and no irregular bleeding – during NuvaRing and COC 
use in 1 large non-comparative study and 2 large randomized 
controlled trials
Study Method (number 
of participants)
Cycles with 
an intended 
bleeding pat-
tern (%)
p value
Dieben et al 2002 NuvaRing (n = 2322) 63.0
Oddsson et al 
2005b (13 cycles)
NuvaRing (n = 512)
150LNG/30EE
COC (n = 518)
58.8–72.8
43.4–57.9
 0.005
for all cycles
Milsom et al 2006 
(13 cycles)
NuvaRing (n = 499)
DRSP/30EE
COC (n = 484)
55.2–68.5
35.6–56.6
 0.01
for all cycles
Abbreviations: COCs, combined oral contraceptives; DRSP, drospirenone; EE, 
ethinyl estradiol.Therapeutics and Clinical Risk Management 2008:4(2) 445
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(21.2 versus 19.0 days, respectively). Fifteen percent of 
NuvaRing users experienced prolonged bleeding (at least 1 
bleeding-spotting episode lasting 10 or more days), compared 
with 31% of pill users (p = 0.04). At the end of the study, the 
women answered exit questions about their perceptions of 
bleeding during the 84-day reference period compared with 
their bleeding at times when they were not using hormonal 
contraception. A signiﬁ  cantly greater proportion of women 
using NuvaRing perceived a decrease in duration of bleed-
ing than those on the COC (p   0.01). Similarly, NuvaRing 
users were less likely to report an increase in ﬂ  ow, although 
this difference did not reach statistical signiﬁ  cance. NuvaR-
ing users were more likely to report no change or a “good” 
change in their bleeding, whereas COC users were more 
likely to report a “bad” change (p   0.01). Hence, alongside 
conventional method initiation, the Quick Start approach also 
gave women using NuvaRing better bleeding patterns than 
those using the COC.
An open-label, single-center, cross-over study was 
carried out in which women were randomly assigned to 
either NuvaRing (ITT = 33) or a COC containing 100 µg 
levonorgestrel and 20 µg EE (100LNG/20EE) (ITT = 31) 
for 3 consecutive 28-day cycles, directly followed by three 
cycles of the alternative study drug (Veres et al 2004). 
During NuvaRing use, there were fewer total bleeding 
days, and the number of inter-menstrual bleeding days 
averaged 0.2 days compared with 1.4 days with COC use 
(p   0.001).
A prospective study during 1 year was carried out in 
280 women who were randomized to either NuvaRing 
(n = 94), or a COC containing 100 µg levonorgestrel and 
20 µg EE (100LNG/20EE) (n = 94), or a COC containing 
60 µg gestodene and 15 µg EE (60 gestodene [GES]/15EE) 
(n = 92) (Sabatini and Cagiano 2006). The incidence of 
irregular bleeding was signiﬁ  cantly lower in the NuvaRing 
group as compared with both COC groups in all cycles 
(p   0.05).
Bleeding patterns in extended ring regimens were exam-
ined in a 1-year open-label, comparative study in 10 European 
centers and 10 centers in the US (Miller et al 2005). The 
women were randomly assigned to 1 of 4 regimens: monthly 
(28-day cycle), every other month (49-day cycle), every third 
month (91-day cycle), or continuous (264-day cycle). The 
mean percentages of bleeding and/or spotting days were 
17.6% (28-day), 15.5% (49-day), 20.9% (91-day), and 24.4% 
(364-day). Discontinuation rates for unacceptable bleeding 
were higher for the 91-day and 364-day cycles compared 
with the 28-day cycle.
Tolerability
Compliance
In the non-comparative studies, compliance with the pre-
scribed NuvaRing regimen was higher in Europe (90.8%) 
than in North America (79.9%) (Roumen et al 2001; Dieben 
et al 2002). The ﬁ  rst experience in daily clinical practice in 
The Netherlands revealed a compliance of 88% (Roumen 
et al 2006). In this study, 3% of women inserted the ring 
too early or too late, and 3.4% removed it too early or too 
late. Another 3.2% had intentionally not complied with the 
prescribed regimen in order to regulate their cycle, whereas 
0.9% reported loss of the ring. In the ﬁ  rst cycle, 2.1% of 
women left the ring outside the vagina for longer than the 
advised 3 h, and 1.8% of women did this during the second 
and third cycles.
In most randomized studies, compliance with the pre-
scribed regimen was high and comparable between the 
NuvaRing groups and the COC groups (87.4% versus 86.6% 
(Oddsson et al 2005a), and 89.2% versus 85.5% (Ahrendt 
et al 2006), of ITT cycles, respectively).
Blood pressure
In the non-comparative studies, no clinically relevant changes 
from baseline were observed in blood pressure (Roumen et al 
2001; Dieben et al 2002). In most randomized studies, blood 
pressure did not change signiﬁ  cantly from baseline in either 
NuvaRing or COC users (Veres et al 2004; O’Connell et al 
2005; Oddsson et al 2005a; Ahrendt et al 2006; Roumen and 
Dieben 2006; Sabatini and Cagiano 2006). In 1 study, 4 sub-
jects in the NuvaRing group (0.8%) and 8 in the COC group 
(1.5%) experienced hypertension (Oddsson et al 2005a).
Body weight
In the non-comparative European study, mean body weight 
increased by 0.43 ± 3.35 kg over the 13 cycles of treatment 
(Roumen et al 2001). A decrease in body weight from screen-
ing to the last visit of  7% was reported for 8% of the women 
while an increase in body weight of  7% was reported for 
10% of women. The combined data of the non-comparative 
European and American studies showed a mean body weight 
increase by 0.84 ± 3.81 kg over the 13 cycles of treatment 
(Dieben et al 2002). In most randomized studies no marked 
changes in body weight were seen between comparator 
groups (O’Connell et al 2005; Roumen and Dieben 2006; 
Sabatini and Cagiano 2006).
In the study of Oddsson et al (2005a), fewer NuvaRing 
users had an increase of  7% in body weight from base-
line than COC (150LNG/30EE) users (8.4% versus 9.8%, Therapeutics and Clinical Risk Management 2008:4(2) 446
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respectively), and more women had a decrease of  7% 
(6.8% versus 5.0%, respectively). However, no signiﬁ  cant 
differences between groups in body weight were found at 
study end.
In the study of Milsom et al (2006) which compared 
NuvaRing with DRSP/30EE, effects on body weight and 
body composition were relatively small and similar with both 
contraceptives over 1 year. For the NuvaRing ITT group, the 
estimated mean body weight change from baseline to the 
last assessment was 0.37 kg (two-sided 95% CI 0.10–0.64). 
For the COC ITT group, the estimated mean bodyweight 
change from baseline was –0.03 kg (2-sided 95% CI –0.29 
to 0.23). In both cases, the upper limit of the 2-sided 95% 
CI was below the pre-speciﬁ  ed 1.5 kg, and therefore it was 
concluded that weight neutrality of both NuvaRing and the 
COC was demonstrated. Individual data were not given.
In the Quick Start trial, the women were weighed upon 
enrolment and at exit after three cycles (NuvaRing  = 82; 
COC = 79) (O’Connell et al 2005; Westhoff et al 2005). Par-
ticipants gained an average of 2.8 lb over 3 months (95% CI 
1.9–3.6 lb; p   0.001). Weight change ranged from an 11-lb 
weight loss to a 20-lb weight gain (SD = 5.5). Subjects under-
went an average increase in their BMI of 0.6 kg/m2, ranging 
from a decrease of 1.8 kg/m2 to an increase of 3.2 kg/m2 
(SD = 0.9). These gains were similar between NuvaRing and 
COC groups (NuvaRing = 2.5 lb, COC = 3.1 lb (p = 0.49); 
NuvaRing = 0.53 kg/m2, COC = 0.58 kg/m2 (p = 0.76)), 
regardless of weight class, baseline weight, baseline BMI or 
the season of study enrolment or exit. Therefore, a small, but 
clinically unimportant weight gain was demonstrated with 
both contraceptives. Again, individual data were not given.
Premenstrual syndrome 
and dysmenorrhea
The ﬁ  rst experience in daily clinical practice in The Nether-
lands showed that during the ﬁ  rst three months of NuvaRing 
use, in comparison with the preceding contraceptive method, 
the percentage of women with complaints of dysmenorrhoea 
decreased from 42% to 26% (p   0.0001), and of those with 
complaints of PMS from 45% to 29% (Roumen et al 2006). 
After 1 year of treatment, moderate or severe PMS or dys-
menorrhea decreased in both the NuvaRing and COC groups 
(DRSP/30EE) with no apparent differences between the 
treatments (Milsom et al 2006). The proportion of subjects 
reporting moderate or severe PMS symptoms decreased 
from 12.6% to 4.5% in the NuvaRing group and from 
14.7% to 4.7% in the COC group (screening versus cycle 
13). The proportion of subjects reporting moderate or severe 
dysmenorrhea also decreased at study end compared with 
screening (decreasing from 17.4% to 5.9% in the NuvaRing 
group and from 19% to 6.4% in the COC group).
Negative mood impact (irritability and depression), 
however, was experienced less by NuvaRing users (4.2%) 
than by COC (100LNG/20EE and 60GES/15EE) users (8.5% 
and 8.6%, respectively) (p   0.05) (Sabatini and Cagiano 
2006).
Adverse events
In the combined data of the non-comparative European and 
American studies, 65.5% of women reported at least one 
adverse event, of which 37.5% were considered by the inves-
tigator as at least possibly related to NuvaRing use (Dieben 
et al 2002). The most frequently reported adverse events 
were headache, vaginitis, and leukorrhea. The incidence of 
breast tenderness and nausea was low. Vaginal discomfort 
was reported by 2.4% of women, and device-related events 
by 4.4%. As shown in Table 3, there were no major differ-
ences in the incidence of these events between the European 
and North American studies (Roumen et al 2001; Dieben 
et al 2002).
The proportion of subjects reporting adverse events was 
comparable in the NuvaRing group and the COC (150LNG/
30EE) group (57.6% and 54.3%, respectively) (Oddsson et al 
2005a). Similar percentages of adverse events considered by 
the investigator to be at least possibly related to study treat-
ment were also observed when the ring was compared with 
150LNG/30EE or DRSP/30EE (NuvaRing: 28.9% (Oddsson 
et al 2005a), and 29.1% (Ahrendt et al 2006) versus COC: 
22.1% (Oddsson et al 2005a), and 23.5% (Ahrendt et al 
2006). The incidence of estrogen-related adverse events such 
as breast tenderness, headache, and nausea were comparable 
between treatment groups (Table 3) (Oddsson et al 2005a; 
Ahrendt et al 2006; Sabatini and Cagiano 2006). The main 
differences in at least “possibly” treatment-related adverse 
events between both groups were the higher incidences of 
local events such as leukorrhea, vaginal discomfort, vaginitis, 
and ring-related events (comprising foreign body sensation, 
coital problems and expulsions) in the NuvaRing groups than 
in the COC groups.
In the combined data of the non-comparative European 
and American studies, 15.1% of women discontinued because 
of adverse events (Roumen et al 2001; Dieben et al 2002). 
The most frequently reported adverse events that resulted 
in withdrawal were device-related problems (2.5%), head-
ache (1.3%), emotional lability (1.2%), weight increase 
(1.0%), bleeding irregularities (0.8%), vaginitis (0.7%), and Therapeutics and Clinical Risk Management 2008:4(2) 447
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leukorrhea (0.6%). Ring-related problems were also the most 
important reason for premature discontinuation (3.9% of 
women) in the Netherlands’ study (Roumen et al 2006).
In most randomized studies, discontinuation due to 
adverse events was higher in the NuvaRing groups than in 
the COC groups (NuvaRing: 11.3% (Oddsson et al 2005a), 
and 12.2% (Ahrendt et al 2006), versus COC: 8.7% (Oddsson 
et al 2005a), and 9.9% (Ahrendt et al 2006), respectively), 
due to the additional ring-related events. In another study, 
however, the discontinuation rate was lower in NuvaRing 
users (11.7%) than in COC (100LNG/20EE and 60GES/
15EE) users (22.3% and 30.4%, respectively) (Sabatini and 
Cagiano 2006).
In the “genital symptoms” study, Veres et al reported that 
the ring never slipped (ring descent with bearing down) in 46 
(71.9%) NuvaRing users, while 6 (9.4%) users reported ring 
slippage at least once a week or more (Veres et al 2004). Ring 
slippage was not associated with an increase in vaginal wet-
ness scores or any examination or laboratory ﬁ  nding. In this 
study, 72% of men never or rarely felt the ring during coitus, 
92% reported no change in sensation during intercourse, and 
87% did not feel the ring move during intercourse. Of the 
24 men who reported 10 or more coital events with ring use, 
4 (16%) reported that the ring would sometimes come out 
during coitus and 2 of these men thought that it interrupted 
sexual activity.
In the study by Guida et al (2005), 89% of women and 
68% of partners never felt NuvaRing during sexual inter-
course (10% of women and 24% of partners felt it occasion-
ally, and 1% of women and 8% of partners always felt it).
The open-label, randomized, cross-over study of Veres 
et al (2004) was speciﬁ  cally designed to investigate genital 
symptoms, signs, examination, and laboratory ﬁ  ndings with 
NuvaRing use compared with 100LNG/20EE. At baseline, 
15% of women had yeast on culture; during NuvaRing use, 
18.8% of women were positive for yeast by culture com-
pared with 22.5% of women during COC use (p = 0.12). At 
baseline, 83.8% of women were positive for any Lactobacil-
lus by culture, and at subsequent visits this percentage was 
similar and not different by method (p = 0.28). However, the 
concentration of Lactobacillus colony-forming units positive 
for hydrogen peroxide (H2O2) production increased during 
Table 3 Percentage of women reporting adverse events with NuvaRing and a COC in two non-comparative studies and three 
randomized controlled trials
Adverse event Method NuvaRing (n = 2322) 
(Europe3 -America4)
NuvaRing (n = 512) vs 
150LNG/30EE COC 
(n = 518)5
NuvaRing 
(n = 499) vs 
DRSP/30 EE COC 
(n = 484)6
NuvaRing 
(n = 94) vs 
100LNG/20EE 
COC (n = 94)7
NuvaRing 
(n = 94) 
vs 60GES/
15EE COC 
(n = 92) 7
Breast tenderness NuvaRing 2.6 (1.9–3.3) 3.1 3.2 4.2 4.2
COC 1.3 4.7 6.3 6.5
Headache NuvaRing 5.8 (6.6–5.0) 7.2 6.8 6.3 6.3
COC 5.8 7.6 9.5 9.7
Nausea NuvaRing 3.2 (2.8–3.6) 2.7 0.8 2.1 2.1
COC 4.0 3.7 7.4 5.4
Leukorrhea NuvaRing 4.8 (5.3–4.2) 3.5 3.2 - -
COC 0.2 1.0 - -
Vaginal discomfort NuvaRing 2.4 (2.2–2.6) - 1.4 - -
COC - 0.0 - -
Vaginitis NuvaRing 5.6 (5.0–6.2) 3.9 4.6 - -
COC 1.0 2.1 - -
Ring-related events1 NuvaRing 4.4 (3.8–5.0) 4.7 6.6 - -
COC 0.0 0.42 --
1Ring-related adverse events comprise foreign body sensation, coital problems, and expulsions.
2dyspareunia.
3Roumen et al 2001.
4Dieben et al 2002.
5Oddsson et al 2005a.
6Ahrendt et al 2006.
7Sabatini and Cagiano 2006.
Abbreviations: COCs, combined oral contraceptives; DRSP, drospirenone; EE, ethinyl estradiol; GES, gestodene; LNG, levonorgestrel.Therapeutics and Clinical Risk Management 2008:4(2) 448
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NuvaRing use (2.67-fold difference, 95% CI 1.49–4.78; 
p   0.001) and increased over baseline values, possibly due 
to some sort of preferential delivery of EE to the vaginal tissue 
and suggesting improvement of the vaginal ﬂ  ora. All other 
examination and laboratory ﬁ  ndings were not signiﬁ  cantly 
different, including Nugent Gram stain score, vaginal white 
blood cell count, vaginal pH values and discharge weight. 
Most subjects reported few genital symptoms with either 
method, but 63% of subjects reported vaginal wetness during 
NuvaRing use compared with 43% during COC use. Most 
vaginal symptoms were scored as mild, and a severe score 
was very rare and sporadic. Vaginal wetness had the highest 
symptom score among NuvaRing users, but the scores were 
still quite low considering they represent 3-cycle averages 
of 28-day totals. There was a non-signiﬁ  cant trend over the 
entire study of decreased reporting of symptoms, with on 
average 20% fewer total symptoms reported after cross-over 
(p = 0.28), perhaps reﬂ  ecting improved method tolerance over 
time for both methods. However, both the ring-ﬁ  rst and 
pill-ﬁ  rst subjects reported on average more vaginal wetness 
during NuvaRing use than during COC use (2.74-fold dif-
ference, 95% CI 1.80–4.18; p   0.001). There was also a 
carry-over effect for total symptoms, with ring-ﬁ  rst subjects 
reporting more symptoms with subsequent pill use than pill-
ﬁ  rst-subjects (p = 0.045). Women who reported more vaginal 
wetness did not differ on laboratory ﬁ  ndings from women who 
did not report this symptom, except for increased cervical 
ectopy at baseline, to predict the occurrence of this symptom 
and the ﬁ  nding of leukorrhea on examination (p = 0.03).
These ﬁ  ndings were conﬁ  rmed in another study (Sabatini 
and Cagiano 2006), in which after three cycles vaginal dry-
ness was reported by less NuvaRing users (2.1%) than by 
COC (100LNG/20EE and 60GES/15EE) users (12.7% and 
30.4%, respectively) (p   0.005).
Serious adverse events
In most studies, no serious adverse events were reported 
(Roumen et al 2001; Dieben et al 2002; Veres et al 2004; 
O’Connell et al 2005; Roumen and Dieben 2006). One case 
of a cerebral venous sinus thrombosis was reported in the 
Netherlands’ study (Roumen et al 2006), and 3 cases (0,2%) 
of deep vein thrombosis, possibly related to study medication, 
were reported in the NuvaRing groups (Miller et al 2005; 
Oddsson et al 2005a; Ahrendt et al 2006).
Acceptability
In the combined data of the non-comparative European 
and North-American studies, the proportion of women 
who reported at least occasionally feeling the ring during 
intercourse was 18% and higher in the discontinuers (23%) 
than the completers (15%) (Roumen et al 2001; Dieben et al 
2002). The percentage of partners feeling the ring during 
intercourse was 32% (discontinuers 37%, completers 29%). 
Most partners, however, in both the completers (83%) and 
the discontinuers (83%) groups did not object to women 
using the ring. From all participating women, 85% were 
satisﬁ  ed or very satisﬁ  ed with the ring at last assessment, 
and 90% of respondents (97% in completers and 75% in 
discontinuers) indicated that they would recommend the ring 
to others. There were no major differences between Europe 
and North-America.
Compared to the preceding method of contraception, the 
percentage of (very) satisﬁ  ed users increased from 34% to 
72% during NuvaRing use in The Netherlands, whereas the 
percentage of (very) dissatisﬁ  ed users decreased from 44% to 
16% (Roumen et al 2006). Of the study population, 82% of 
women and 67% of their partners never or rarely felt the ring 
during intercourse. For the women who completed all 3 cycles, 
these percentages were 85% and 68%, respectively, and for 
the group of women who discontinued, these percentages were 
65% and 62%, respectively. In couples who felt the ring during 
intercourse, 56% of women and 38% of their partners found 
it unpleasant. From the 82.6% of women who completed the 
3-month study period, 80% continued with NuvaRing use. The 
most frequently reported reasons for satisfaction (more than 
one answer possible) were once-a month administration (54%), 
low hormonal dose (31%), and ease of use (27%). The most 
frequently reported reasons for dissatisfaction were general 
adverse events (16%), local adverse events like expulsion 
(8%), and/or inconvenience during intercourse (7%).
In the comparison with DRSP/30EE, both NuvaRing 
and COC were found to be highly acceptable (Ahrendt et al 
2006). The majority of women were satisﬁ  ed with NuvaRing 
(59% very satisﬁ  ed, 25% satisﬁ  ed) and the COC (54% very 
satisﬁ  ed, 33% satisﬁ  ed) and would recommend the method 
to others (87% NuvaRing, 92% COC).
In the comparison with 100LNG/20EE, average levels of 
satisfaction reported at exit visit were 4.3 ± 0.9 for NuvaRing 
use and 3.6 ± 1.0 for COC use (p   0.001), based on a scale 
of 1 to 5, where 1 = dissatisﬁ  ed and 5 = best method (Veres 
et al 2004). At study completion, 50% of all women planned 
to continue using the ring, compared with 28% of women 
who planned to continue using the COC (6% chose another 
method and 16% chose no contraception). Ninety-three per-
cent of partners said that they would deﬁ  nitely or possibly 
recommend NuvaRing to other couples.Therapeutics and Clinical Risk Management 2008:4(2) 449
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User satisfaction and method continuation were also 
assessed in the previously described group of women with a 
Quick Start approach (O’Connell et al 2005; Westhoff et al 
2005; Schafer et al 2006). At 3 months, 174 subjects (87%) 
had follow-up interviews (Schafer et al 2006). Signiﬁ  cantly 
more NuvaRing users than COC users were very satisﬁ  ed 
with their method (61% versus 34%; p = 0.003), and chose 
to continue their method (79% versus 59%; p   0.001). Both 
the higher user satisfaction and the continuation of NuvaRing 
for birth control were not associated with prior use of vaginal 
contraceptives or products, masturbation, discomfort with 
intercourse or other behaviors that involve genital touching 
such as waxing and shaving pubic hair or having tattoos 
and/or body piercings. Neither demographic characteristics 
nor vaginal experiences identiﬁ  ed successful ring users.
In an open-label, randomized, single center study, the 
inﬂ  uence of intravaginal and oral hormonal contraception 
on the sexual life of women and their partners was evaluated 
(Guida et al 2005). Healthy women with a permanent partner 
and an active sexual life were randomly assigned to NuvaR-
ing (ITT = 26) or a COC containing 150 µg desogestrel and 
20 µg EE (ITT = 25) for 6 consecutive 28-day cycles. A 
control group was also included, consisting of 25 women not 
using hormonal contraception. Sexual activity of the women 
and their partners was assessed by the Interviewer Ratings 
of Sexual Function (IRSF) questionnaire, at the start of the 
study and after cycles 3 and 6. Compared with women not 
using hormonal contraception, women in both the NuvaR-
ing and the COC groups reported a global improvement of 
sexual function after 3 months, which was sustained until the 
6-month assessment. Compared with the group not using hor-
monal contraception, in both contraceptive groups, signiﬁ  cant 
improvements were observed for anxiousness (p   0.001), 
sexual pleasure (p   0.001), frequency and intensity of 
orgasm (p   0.001), satisfaction (p   0.001), sexual interest 
(p   0.01), and complicity (p   0.01). Only women using 
NuvaRing reported a signiﬁ  cant increase in sexual fantasy 
compared with the women using the COC or no hormonal 
contraception (p   0.001). A signiﬁ  cant increase in the fre-
quency of sexual intercourse was seen in both contraceptive 
groups at cycle 3 (p   0.001) and at cycle 6 (p   0.001) in 
comparison with baseline, and with women not using hor-
monal contraception at cycle 3 (p   0.001) and at cycle 6 
(p   0.001). After 3 cycles, a signiﬁ  cant reduction in anxiety 
and an increase in pleasure and satisfaction, frequency and 
intensity of orgasm were reported for partners of women 
in both the NuvaRing and the COC groups. A signiﬁ  cant 
increase in sexual interest, complicity, and sexual fantasy was 
observed only in partners of women using NuvaRing. As for 
the women, the improvement of sexual function in the male 
partners of both contraceptive groups showed substantial 
consistency after 6 months.
The improved sexuality among NuvaRing users was 
conﬁ  rmed in another study, in which after 12 cycles an 
increase of sexual desire and sexual satisfaction was reported 
by more NuvaRing users (75.5%, and 77.6%, respectively) 
than by COC (100LNG/20EE) users (26.5%, and 46.8%, 
respectively) (p   0.005), and COC (60GES/15EE) users 
(30.4%, and 22.8%, respectively) (p   0.005) (Sabatini and 
Cagiano 2006).
Discussion
In this review, contraceptive efﬁ  cacy, cycle control, toler-
ability, and acceptability of NuvaRing as established in 
several large non-comparative multi-center registration 
studies (Roumen et al 2001; Dieben et al 2002), and in daily 
clinical practice (Roumen et al 2006), were compared with 
those of RCTs comparing NuvaRing with COCs (Veres et al 
2004; Guida et al 2005; O’Connell et al 2005; Oddsson et al 
2005a, b; Westhoff et al 2005; Ahrendt et al 2006; Milsom 
et al 2006; Sabatini and Cagiani 2006; Schafer et al 2006). 
The reason for this testing was that results of registration 
studies may be biased by the willingness of the participants 
and the fact, that these studies were funded by, undertaken 
by, analyzed by and the results written up by staff of the 
company which manufactures the CCVR. Although the latter 
is also true for most of the RCTs, these studies represent the 
highest possible level of evidence.
The good contraceptive efﬁ  cacy during the ﬁ  rst year 
of NuvaRing use in the non-comparative studies (Roumen 
et al 2001; Dieben et al 2002) was conﬁ  rmed in the RCTs, 
in which contraceptive efﬁ  cacy was comparable between 
NuvaRing and the COC (Oddsson et al 2005a; Ahrendt et al 
2006). This ﬁ  nding is not surprising, as ovarian suppression 
was shown to be adequate with both methods (Mulders and 
Dieben 2001; Duijkers et al 2004). This result should be 
interpreted with caution, of course, as it is not predictive of 
the long-term contraceptive results.
The incidence of estrogen-related adverse events such 
as breast tenderness, headache, and nausea was low in the 
non-comparative registration studies (Roumen et al 2001; 
Dieben et al 2002). Although this ﬁ  nding could be conﬁ  rmed 
in the RCTs, the incidence of estrogen-related adverse events 
was not signiﬁ  cantly lower with NuvaRing compared with 
the COC (Oddsson et al 2005a; Ahrendt et al 2006; Sabatini 
and Cagiano 2006). This is somewhat disappointing, as the Therapeutics and Clinical Risk Management 2008:4(2) 450
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systemic exposure to EE with NuvaRing (releasing 15 µg EE 
per day) compared with that for a COC containing 30 µg EE 
per pill, is approximately 50% (Timmer and Mulders 2000; 
van den Heuvel et al 2005). In the non-comparative studies, 
no clinically relevant changes from baseline were observed in 
blood pressure and body weight (Roumen et al 2001; Dieben 
et al 2002). Also no apparent differences between NuvaRing 
and the COC were found in blood pressure changes (Veres 
et al 2004; O’Connell et al 2005; Oddsson et al 2005a; 
Ahrendt et al 2006; Roumen and Dieben 2006; Sabatini and 
Cagiano 2006), body weight changes (Oddsson et al 2005a; 
Westhoff et al 2005; Roumen and Dieben 2006; Sabatini and 
Cagiano 2006; Schafer et al 2006), or decreasing rates of 
PMS and dysmenorrhea complaints (Milsom et al 2006).
An important ﬁ  nding in the non-comparative studies was 
the good cycle control with NuvaRing (Roumen et al 2001; 
Dieben et al 2002; Roumen et al 2006). This was conﬁ  rmed 
in the RCTs, in which a better cycle control with NuvaRing 
than with the COC was a consistent ﬁ  nding (Sabatini and 
Cagiano 2006). Cycle control is a key factor that affects 
contraceptive acceptability, compliance, and convenience, 
especially for the vaginal route of administration. The inci-
dence of an intended bleeding pattern, deﬁ  ned as a cycle 
with only a withdrawal bleeding in the hormone-free week, 
was high in the combined data of the large international 
registration studies (Roumen et al 2001; Dieben et al 2002). 
This high incidence of an intended bleeding pattern with 
NuvaRing was conﬁ  rmed in the RCTs, and shown to be 
signiﬁ  cantly higher in most cycles with NuvaRing than with 
the COC (Oddsson et al 2005b; Milsom et al 2006). This was 
mainly due to a signiﬁ  cantly lower incidence of withdrawal 
bleeding persisting after the hormone-free week in the 
NuvaRing groups compared with the COC. This continued 
withdrawal bleeding consisted mainly of spotting days in 
both groups. A better bleeding pattern with NuvaRing than 
with the COC was also found when the same women used 
both methods in a cross-over study (Veres et al 2004). Even 
after initiation of the contraceptive method regardless of 
menstrual cycle day, the bleeding patterns with NuvaRing 
were better than with the COC (Westhoff et al 2005). The 
superior cycle control with NuvaRing is remarkable, as the 
total daily dose of EE is only half of that of a 30 µg EE COC. 
So, other mechanisms must be responsible for this. A local 
effect is unlikely, as no elevated concentrations of EE and 
ENG were found in the endometrial and myometrial tissues 
with NuvaRing compared with a 20 EE µg COC (Roumen 
and Dieben 2006). It is most obvious, therefore, that the 
considerably lower variation in daily EE serum levels with 
NuvaRing compared with the COC is an important causative 
factor (van den Heuvel et al 2005).
It is not surprising, that the vaginal route of hormone 
administration was associated with higher incidences of 
local adverse events such as leukorrhea, vaginal discomfort, 
vaginitis, and ring-related events comprising foreign body 
sensation, coital problems and expulsions, than the oral route 
in both the non-comparative studies and the RCTs (Roumen 
et al 2001; Dieben et al 2002; Oddsson et al 2005a; Ahrendt 
et al 2006). In one study, increased vaginal wetness during 
NuvaRing use was accompanied by an improvement of the 
bacterial ﬂ  ora in the vagina (Veres et al 2004). In another 
study, less vaginal dryness was reported by NuvaRing users 
(Sabatini and Cagiano 2006). As could be expected, discon-
tinuation rates due to local and ring-related adverse events 
were also higher in the NuvaRing groups than in the COC 
groups (Oddsson et al 2005a; Ahrendt et al 2006). The inci-
dences of serious adverse events were low and comparable 
in both groups. However, the number of participants in the 
studies was too small and the duration of the studies too 
short to provide any reliable information on the incidence 
of infrequent but serious adverse events like thromboembo-
lism. Unfortunately, the inﬂ  uence of the lower EE exposure 
with NuvaRing on coagulation factors and lipid metabolism 
remains unknown, as no RCTs between NuvaRing and the 
COC on these important metabolic parameters have been 
published yet. In two different open-label, non-randomized 
comparative studies, both NuvaRing and a 150LNG/30EE 
COC were associated with minimal effects on hemostatic 
variables and on lipid proﬁ  le (Magnusdóttir et al 2004; 
Tuppurainen et al 2004).
In the non-comparative studies and the RCTs, both 
NuvaRing and the COC were found to be highly accept-
able methods of contraception (Roumen et al 2001; Dieben 
et al 2002; Ahrendt et al 2006; Roumen et al 2006). Com-
pared with women not using hormonal contraception, both 
women using NuvaRing and the COC reported a global 
improvement of sexual function (Guida et al). The higher 
satisfaction and stronger preference for method continua-
tion of NuvaRing users is remarkable, and its explanation 
did not emerge from the studies (Veres et al 2004; Schafer 
et al 2006). The most important reason is possibly, that 
the once-a-month use of NuvaRing is easy and more con-
venient for many women (Roumen et al 2006), although 
NuvaRing compliance was not different from the daily pill 
regimen (Dieben et al 2002; Oddsson et al 2005a; Ahrendt 
et al 2006). Also, the superior cycle control is a possible 
attractive reason for many women. A third argument could Therapeutics and Clinical Risk Management 2008:4(2) 451
NuvaRing
be, that many women feel that the lower daily EE dose and 
the less ﬂ  uctuating hormone levels with the CCVR are less 
harmful for their general health (Roumen et al 2006). Lastly, 
the signiﬁ  cant increase in sexual desire, satisfaction and 
fantasy of women and partners of women using the CCVR 
is a possible contributing factor (Guida et al 2005; Sabatini 
and Cagiano 2006).
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